Abstract
Over the last two decades, progress towards new drugs for the treatment of Chagas' disease has been disappointing. However, as a result of the parasite genome sequencing projects, the possibility of identifying novel drug targets through genomics, proteomics and bioinformatics has never been better. Progress towards the development of novel therapeutics, from target identification and validation by chemical and genetic means through to rational drug design, is illustrated with reference to the metabolism and functions of trypanothione, with particular emphasis on trypanothione reductase, one current drug target of choice.
| Original language | English |
|---|---|
| Pages (from-to) | 179-187 |
| Number of pages | 9 |
| Journal | Medicina |
| Volume | 59 |
| Issue number | SUPPL. 2 |
| Publication status | Published - 1999 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Drug discovery
- Leishmaniasis
- Target validation
- Trypanosomiasis
- Trypanothione reductase
ASJC Scopus subject areas
- General Medicine
Fingerprint
Dive into the research topics of 'Future prospects for the chemotherapy of Chagas' disease'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver